AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02288325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo taken orally once daily.
Study NCT04291313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (90µg)
Description: The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
Study NCT04291313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 (10µg)
Description: This intervention serves as a control as they get the current recommended vitamin D dose
Study NCT02996409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HVIGI
Description: High Volume Image-Guided Injection with a saline/lidocain solution
Study NCT02996409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LVIGI
Description: Placebo control with injection of a saline/lidocain solution (low volume)
Study NCT02996409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive exercise program
Description: A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
Study NCT02996409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive exercise program
Description: A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
Study NCT05496205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.
Study NCT05496205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for each formulations
Study NCT01014546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given PO
Study NCT01014546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given PO
Study NCT01014546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01014546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04587687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT04587687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT04493554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of vasopressin (20 IU) intranasally
Study NCT04493554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo intranasally
Study NCT01204073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-441
Description: TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle
Study NCT00337129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: 1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
Study NCT01738009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of flow limitation
Study NCT01382134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, desmopressin
Description: Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
Study NCT01382134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, desmopressin
Description: Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
Study NCT00003119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00003119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT03977870 — intervention group
Intervention type: OTHER
Intervention: vital status determination
Description: consultation of national registries
Study NCT01095276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmozyme (nebulized dornase alpha)
Description: nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
Study NCT01095276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
Study NCT00304850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: polyamine-free diet
Description: Polyamine-free diet in the 7 days befor surgery
Study NCT00304850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection
Study NCT00304850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine or placebo
Description: Peroperative and post operative (48h) ketamine injection
Study NCT01479075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intransal insulin
Description: 4x 40mU intranasal insulin
Study NCT01479075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01479075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01479075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Study NCT01479075 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study NCT00003119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT03885661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG [Vascepa]
Description: Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
Study NCT02282540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iodixanol to the Eustachian tube
Description: Application of iodixanol to the middle ear for imaging of the ET.
Study NCT02822014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FDG-PET/CT
Description: We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
Study NCT00003119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00003119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01594580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnated scrubs
Description: Scrubs are impregnated with an antimicrobial product
Study NCT01594580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-impregnated scrubs
Study NCT00958685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
Study NCT00958685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
Study NCT02192216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02177773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo Gallium Ga 68-DOTA-TOC PET/CT
Study NCT02177773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-Edotreotide
Description: Given Intravenously (IV) before imaging
Study NCT02177773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo gallium Ga 68-DOTA-TOC PET/MRI
Study NCT02177773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
Study NCT01818414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
Study NCT01818414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 4 mg of buccal folic acid, 3 hours prior to planned D\&E
Study NCT02043093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sources of Strength
Description: Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos.
Study NCT04215653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study NCT04215653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study NCT01476046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057 single dose
Description: Single intravenous dose
Study NCT01476046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose
Study NCT01281930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full packing into abscess cavity
Description: After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
Study NCT01281930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wick placement into abscess cavity
Description: After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
Study NCT03524404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 Week Intervention
Description: Weekly interactive webinars based on the DPP curriculum at senior center.
Study NCT02605057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel
Study NCT02605057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovobet(r) Ointment
Study NCT02187757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Dietary Supplement (Prelipid 500 mg capsules)
Description: Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
Study NCT02187757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04215653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Placebo
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study NCT04215653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anaprazole Sodium Placebo
Description: administered orally once every 30-60 minutes before breakfast for 4 weeks
Study NCT01839734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone 24 mcg by mouth (PO) once-daily
Study NCT03243526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluid therapy
Description: fluid resuscitation guided by CVP or PPV
Study NCT03243526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid therapy
Description: fluid resuscitation guided by CVP or PPV
Study NCT00401570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab
Description: Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
Study NCT00401570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
Study NCT00783536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept + Methotrexate
Study NCT00783536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDS
Study NCT04082026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions EASE)
Description: EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems
Study NCT04082026 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Early Adolescent Skills for Emotions EASE)
Description: EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems
Study NCT04463407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students
Description: An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.
Study NCT01184378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dairy lipids and soluble milk proteins
Description: one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
Study NCT01184378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dairy lipids and soluble milk proteins
Description: one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
Study NCT00172094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPS 1776 (800 mg)
Description: NPS 1776 (800 mg) powder
Study NCT00172094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo in non-carbonated fruit flavored drink (150 ml)
Study NCT00172094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPS 1776 (400 mg)
Description: NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
Study NCT03558581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Study NCT03451253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acid mixture beverage
Description: commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
Study NCT03451253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose-based sports drink
Description: Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
Study NCT01598844 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement via a transapical access
Study NCT02996227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
Study NCT02996227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural catheters will be inserted preoperatively.
Study NCT02996227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
Study NCT02996227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
Study NCT02147834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
Study NCT02147834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: sugar pill manufactured to mimic ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
Study NCT00695461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v in oatmeal drink
Description: Bacteria in a concentration of 10(9) CFU/ml
Study NCT00695461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal drink
Description: Oatmeal drink as in arm 1 but without bacteria added.
Study NCT00671112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.
Study NCT00671112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
Study NCT01804946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficiency of Ergoferon in treatment of Influenza
Study NCT01804946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Safety and Efficiency in treatment of Influenza
Study NCT03096860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active alcohol consumption
Description: Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
Study NCT03096860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo consumption
Description: Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
Study NCT03059043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: viscoelastic-free implantation system
Description: Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
Study NCT03059043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard viscoelastic-assisted Implantation system
Description: This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
Study NCT02859766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar pegol
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
Study NCT00063934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00063934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00063934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00063934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00063934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC